Candel Therapeutics, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Candel Therapeutics, Inc.
CADL · Nasdaq · USD · Market cap $694M · 55 employees
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price6.20 USD at the 13 Nov 2026 close
- Fair valueUnder review: our model's value is 2.68x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-15
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Candel Therapeutics, Inc. holds its Distribution at $6.20. Consolidating, no directional conviction, held for 1 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $6.20 |
| Valuation | N/A trailing · -14.51 forward price to earnings |
| Values screen | Not scored · score 90.0 |
| Beta | -0.31 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 7.65% | Below 33% | Interest-bearing debt is just 7.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 18.68% | Below 33% | Cash held in interest-bearing accounts and securities is 18.7% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Candel Therapeutics, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Candel Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value under review. Our model's value is 2.68x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +263% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -14.5x |
| EPS, trailing | -1.46 |
| EPS, forward | -0.63 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -81.8%not currently earning a positive return on equity |
| FCF yield | -5.15% |
| Debt to equity | 0.39minimal debt: a conservative balance sheet |
| Current ratio | 16.09comfortably covers its short-term bills |
| Beta | -0.31barely tracks the market's swings |
| Short interest, float | 0.22% |
| 52-week range | 4.35 - 14.00 |
| Market cap | $694M |
| Employees | 55 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCADL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 2% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (8 analysts) rates it strong buy, with a mean price target of $20.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Candel Therapeutics to Present at the SITC 2026 Annual Meeting Yahoo Finance · 2 Oct 2026
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 1 Oct 2026
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI Yahoo Finance · 1 Oct 2026
- CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’ Yahoo Finance · 30 Sep 2026
- Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer Yahoo Finance · 30 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-23 | MANNING PAUL B. | Director | 550,458 | $2,999,996 | |
| 2025-07-28 | NICHOLS WILLIAMS GARRETT | Officer | 937 | $6,540 | |
| 2025-07-28 | NICHOLS WILLIAMS GARRETT | Officer | 937 | $1,209 | |
| 2025-06-30 | NICHOLS WILLIAMS GARRETT | Officer | 781 | $3,936 | |
| 2025-06-30 | NICHOLS WILLIAMS GARRETT | Officer | 781 | $1,007 | |
| 2025-06-25 | PAPA JOSEPH C | Director | 64,239 | $299,996 | |
| 2025-06-25 | MANNING PAUL B. | Director | 1,070,663 | $4,999,996 | |
| 2025-06-25 | NABEL GARY J. | Director | 5,353 | $24,999 | |
| 2025-06-25 | MARTELL CHRISTOPHER | Director | 111,349 | $520,000 | |
| 2025-06-25 | TAK PAUL PETER | Chief Executive Officer | 42,826 | $199,997 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $8.85 | -7.7% | · | $923 | -7.7% |
| 2 months | $4.83 | +69.2% | · | $1,692 | +69.2% |
| 3 months | $4.98 | +64.1% | · | $1,641 | +64.1% |
| 6 months | $6.47 | +26.3% | · | $1,263 | +26.3% |
| 1 year | $5.85 | +39.7% | · | $1,397 | +39.7% |
| 2 years | $7.03 | +16.2% | · | $1,162 | +16.2% |
| 3 years | $1.47 | +455.8% | · | $5,558 | +455.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CADL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.